Brezivaptan
A vasopressin receptor antagonist
| Brezivaptan | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Brezivaptan is a pharmaceutical compound that acts as a selective antagonist of the vasopressin receptor. It is primarily investigated for its potential therapeutic effects in conditions related to the endocrine system, particularly those involving the regulation of water balance and blood pressure.
Pharmacology[edit | edit source]
Brezivaptan functions by inhibiting the action of vasopressin, a hormone that plays a crucial role in the body's retention of water and the constriction of blood vessels. By blocking the vasopressin receptor, Brezivaptan can potentially reduce water retention and lower blood pressure, making it a candidate for treating conditions such as hyponatremia and congestive heart failure.
Mechanism of Action[edit | edit source]
The primary mechanism of action of Brezivaptan involves its selective antagonism of the V1A receptor, a subtype of the vasopressin receptor. This receptor is predominantly found in vascular smooth muscle and the central nervous system. By blocking this receptor, Brezivaptan reduces vasoconstriction and promotes diuresis, which can be beneficial in managing fluid overload conditions.
Clinical Applications[edit | edit source]
Brezivaptan is under investigation for its potential use in treating various medical conditions. Its ability to modulate the effects of vasopressin makes it a promising candidate for managing disorders such as:
- Hyponatremia: A condition characterized by low sodium levels in the blood, often associated with heart failure, liver cirrhosis, and certain kidney diseases.
- Heart Failure: By reducing fluid overload and decreasing vascular resistance, Brezivaptan may help alleviate symptoms of heart failure.
Development and Research[edit | edit source]
Research into Brezivaptan is ongoing, with studies focusing on its efficacy, safety, and potential side effects. Clinical trials are essential to determine the optimal dosing and to identify any long-term impacts of the drug.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
